This is a paid press release. Contact the press release distributor directly with any inquiries.
Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications
Company created following Jazz Pharmaceuticals’ acquisition of Actio Biosciences
Setara plans to advance clinical-stage small molecule TRPV4 inhibitor for treatment of Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, along with other early-stage discovery programs
Investor syndicate comprised of leading healthcare investors including Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, and Regeneron Ventures, as well as Jazz Pharmaceuticals
SAN DIEGO, October 30, 2026–(BUSINESS WIRE)–Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90 million Series A financing. Setara was formed following the closing of Jazz Pharmaceuticals’ acquisition of Actio Biosciences (Actio) for its lead program ABS-1230, an investigational therapy for KCNT1-related epilepsy. Setara intends to advance Actio’s remaining pipeline, led by the clinical-stage small molecule TRPV4 inhibitor, STAR-0871 (formerly ABS-0871), for the treatment of CMT2C and overactive bladder, along with a portfolio of earlier-stage discovery programs. Current investors Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, and Regeneron Ventures participated in the financing, along with new shareholder Jazz Pharmaceuticals as part of the Actio acquisition.
Setara brings together an experienced team and a proven genetics-driven approach to design and development of small molecule precision medicines that address the underlying causes of disease. Building on an approach pioneered, refined, and successfully scaled at Actio, Setara is working to advance a pipeline of precision medicines with the potential to transform the lives of patients. Setara’s “one to many” strategy starts with rare diseases, where human genetics can provide a clear understanding of disease biology, and then also applies those insights to identify opportunities to treat broader patient populations with more prevalent conditions.
“With Setara, we have the opportunity to build on a model that has already demonstrated its potential and apply it to severe, rare diseases with significant unmet need today,” said David Goldstein, Ph.D., co-founder, president and executive chair of Setara. “We are incredibly proud of what we built at Actio and that ABS-1230 for KCNT1-related epilepsy now has the opportunity to advance as part of Jazz. Setara allows us to take the next step in our journey, to carry forward a pipeline of promising programs for rare diseases, with the potential to ultimately reach much broader patient populations.”
